Skip to search formSkip to main contentSkip to account menu

MANGAFODIPIR

Known as: Mn-DPDP, manganese dipyridoxyl diphosphate, manganese-DPDP 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND The majority of patients receiving the platinum-based chemotherapy drug oxaliplatin develop peripheral neurotoxicity… 
Review
2008
Review
2008
PurposeWe compared 18-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography–CT (PETCT) with contrast-enhanced whole-body… 
2008
2008
To develop and validate an objective technique for 3D segmentation of manganese‐enhanced MR images of the optic nerve/tract (ON… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND Anticancer drugs act by increasing intracellular hydrogen peroxide levels. Mangafodipir, a superoxide dismutase (SOD… 
Highly Cited
2005
Highly Cited
2005
Paradoxically, reactive oxygen species (ROS) can promote normal cellular proliferation and carcinogenesis, and can also induce… 
Highly Cited
2000
Highly Cited
2000
PURPOSE To assess whether normal myocardium can be distinguished from infarction at magnetic resonance (MR) imaging with low… 
Highly Cited
1999
Highly Cited
1999
Manganese dipyridoxyl diphosphate (MnDPDP) is a contrast agent for magnetic resonance imaging (MRI) of the liver. Aims of the… 
1995
1995
RATIONALE AND OBJECTIVES.Manganese dipyridoxyl diphosphate (MnDPDP) is a promising contrast agent for magnetic resonance imaging… 
1993
1993
The recently developed paramagnetic hepatobiliary contrast agent manganese dipyridoxyl diphosphate (DPDP) was evaluated in eight…